Xenetic appoints Parslow Interim CEO at $400k salary, $100k retention bonus; separations with former CEO/CSO

Xenetic Biosciences, Inc.

James Parslow appointed Interim CEO effective May 16, 2024; base salary increased to $400,000.
Parslow eligible for $100,000 cash retention bonus if employed for ten months; receives option for 20,000 shares.
Confidential separation agreements with former CEO Jeffrey Eisenberg and former CSO Curtis Lockshin providing severance per existing agreements.
Eisenberg Separation Agreement includes accelerated vesting of all unvested stock options as of May 16, 2024.
Stock option grant vests 1/4 on grant date and 1/4 on each of first three anniversaries, subject to continued employment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Curtis Lockshin

Chief Scientific Officer

XBIO · Xenetic Biosciences, Inc.

Filed: June 21, 2024, 7:59 PM ET

and Curtis Lockshin, the Company’s former Chief Scientific Officer

Departed

Jeffrey F. Eisenberg

Chief Executive Officer

XBIO · Xenetic Biosciences, Inc.

Successor: James F. Parslow
Filed: June 21, 2024, 7:59 PM ET

the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer

Appointed (interim)

James F. Parslow

Interim Chief Executive Officer

XBIO · Xenetic Biosciences, Inc.

Effective: 2024-05-16
Filed: June 21, 2024, 7:59 PM ET

the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..

Role: Chief Scientific Officer

Exact text from the filing

and Curtis Lockshin, the Company’s former Chief Scientific Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..

Role: Chief Executive Officer

Exact text from the filing

the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.

View on SEC.gov

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-004415

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.